Journal ArticleDOI
The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis
Jon M. Hanifin,Thurston M,Thurston M,Omoto M,Omoto M,R. Cherill,R. Cherill,Susan J. Tofte,Graeber M,Graeber M +9 more
Reads0
Chats0
TLDR
In this paper, the reliability of the EASI scoring system was evaluated by assessing inter-and intra-observer consistency, and the results indicated that the evaluators assessed the patients consistently across both study days.Abstract:
:Objective– To test the reliability of the eczema area and severity index (EASI) scoring system by assessing inter- and intra-observer consistency. Design: Training of evaluators, application, and assessment over 2 consecutive days. Setting– An academic center. Patients– Twenty adults and children with atopic dermatitis (AD); cohort 1 (10 patients ≥8 years) and cohort 2 (10 patients <8 years). Interventions– None. Main outcome measure– The EASI was used by 15 dermatologist evaluators to assess atopic dermatitis in cohort 1 and cohort 2 on 2 consecutive days. Inter- and intraobserver reliability were analyzed. Results– Overall intra-evaluator reliability of the EASI was in the fair-to-good range. Inter-evaluator reliability analyses indicated that the evaluators assessed the patients consistently across both study days. Conclusions– This study demonstrated that the EASI can be learned quickly and utilized reliably in the assessment of severity and extent of AD. There was consistency among the evaluators between consecutive days of evaluation. These results support the use of the EASI in clinical trials of therapeutic agents for AD.read more
Citations
More filters
Journal ArticleDOI
Real-life experience on effectiveness and safety of dupilumab in adult patients with moderate-to-severe atopic dermatitis
M C Fargnoli,Maria Esposito,Silvia Ferrucci,Giampiero Girolomoni,A. Offidani,Annalisa Patrizi,Ketty Peris,Antonio Costanzo,G. Malara,Giovanni Pellacani,Marco Romanelli,Paolo Amerio,Antonio Cristaudo,Maria Laura Flori,Alberico Motolese,P. Betto,Cataldo Patruno,Paolo D. Pigatto,R. Sirna,Giuseppe Stinco,Iris Zalaudek,Luca Bianchi,V. Boccaletti,S.P. Cannavò,Francesco Cusano,Serena Lembo,R Mozzillo,Richard L. Gallo,Concetta Potenza,Franco Rongioletti,Rossana Tiberio,Teresa Grieco,Giuseppe Micali,Severino Persechino,M Pettinato,S. Pucci,Eleonora Savi,Luca Stingeni,Antonino Romano,Giuseppe Argenziano +39 more
TL;DR: Dupilumab significantly improved disease severity, pruritus, sleep loss and quality of life with an acceptable safety profile in adults with moderate-to-severe AD in a real-life Italian multicentre retrospective cohort.
Journal ArticleDOI
Topical pimecrolimus: a review of its clinical potential in the management of atopic dermatitis.
Keri Wellington,Blair Jarvis +1 more
TL;DR: Topical pimecrolimus 1.0% cream provides a promising and well tolerated treatment option in the management of infants, children and adults with mild to moderate atopic dermatitis, and has shown no potential for skin atrophy.
Journal ArticleDOI
Onset of action of pimecrolimus cream 1% in the treatment of atopic eczema in infants
Roland Kaufmann,Regina Fölster-Holst,Peter Höger,Diamant Thaçi,Helena Löffler,Doris Staab,Matthias Bräutigam +6 more
TL;DR: Pimecrolimus cream 1% was well tolerated and effective in patients with mild to very severe atopic eczema, with rapid onset of action and no disease rebound after discontinuation.
Journal ArticleDOI
The Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD): The development and reliability testing of a novel clinical outcome measurement instrument for the severity of atopic dermatitis.
Eric L. Simpson,Robert Bissonnette,Lawrence F. Eichenfield,Emma Guttman-Yassky,Brett A. King,Jonathan I. Silverberg,Lisa A. Beck,Thomas Bieber,Kristian Reich,Kenji Kabashima,Marieke M B Seyger,Elaine C. Siegfried,Georg Stingl,Steven R. Feldman,Alan Menter,Peter C.M. van de Kerkhof,Gil Yosipovitch,Carle Paul,Philippe Martel,Ariane Dubost-Brama,John Armstrong,Rajeev Chavda,Steve Frey,Y. Joubert,M. Milutinovic,A. Parneix,Henrique D. Teixeira,Chen Yen Lin,Luna Sun,Paul Klekotka,Brian J. Nickoloff,Yves Dutronc,Lotus Mallbris,Jonathan Janes,Amy M. DeLozier,Fabio P. Nunes,Amy S. Paller +36 more
TL;DR: A validated IGA scale and training module were developed with the intent of harmonizing assessment of disease severity in AD trials, and strong reliability and excellent agreement between assessments were observed.
Journal ArticleDOI
A randomized controlled trial of pimecrolimus cream 1% in adolescents and adults with head and neck atopic dermatitis and intolerant of, or dependent on, topical corticosteroids.
Dedee F. Murrell,Stefano Calvieri,J.-P. Ortonne,V. C. Ho,S. Weise-Riccardi,Nathalie Barbier,Carle Paul +6 more
TL;DR: There is a need for alternative treatments for atopic dermatitis of the face and neck as long‐term use of topical corticosteroids (TCS) is associated with skin atrophy and telangiectasia and some patients develop allergy, intolerance or other side‐effects.
References
More filters
Book
The design and analysis of clinical experiments
TL;DR: The Parallel Groups Design as mentioned in this paper is a special case of the Parallel Groups Study, and it is used to control for prognostic variables in linear regression analysis of linear regressions of linear models.
Journal ArticleDOI
Severe psoriasis--oral therapy with a new retinoid.
T. Fredriksson,Ulf Pettersson +1 more
TL;DR: Ro 10--9359 proved to be an extremely potent antipsoriatic drug and a more than 90% reduction of psoriatic lesions could be seen in 10 patients out of 20 after 4-8 weeks of treatment.
Journal ArticleDOI
Severity Scoring of Atopic Dermatitis: The SCORAD Index
K.U. Schallreuter,Ch. Levenig,J. Berger,J. Umbert,R.K. Winkelmann,L. Wegener,O. Correia,Olivier Chosidow,P. Saiag,S. Bastuji-Garin,J. Revuz,Jean-Claude Roujeau,R. Situ,D.R. Inman,S.E.G. Fligiel,J. Varani,R.E. Schopf,J. Dobmeyer,T. Dobmeyer,B. Morsches,K. Holubar,G.E. Piérard,O. Bongard,H. Bounameaux,P. Corcuff,J.-L. Lévêque,J. Brasch,E. Christophers,G.T. Nahass,M. Sisto,S.A. Wagner,R.U. Peter,O. Adam,T. Ruzicka,J. McGrath,N.P. Burrows,R. Russell Jones,R.A.J. Eady,S. Veraldi,G. Rizzitelli,G. Lunghi,R. Cardone,R.M. Trüeb,G. Burg,F. Wantke,G. Fleischl,M. Götz,R. Jarisch,G. Tadini,E. Ermacora,S. Cambiaghi,A. Brusasco,R. Cavalli +52 more
TL;DR: Assessment methods for atopic dermatitis are not standardized, and therapeutic studies are difficult to interpret, so consensus on these methods is needed to obtain a consensus on them.
Journal ArticleDOI
Large sample standard errors of kappa and weighted kappa.
TL;DR: The statistics kappa and weighted kappa (Cohen, 1960) were introduced to provide coefficients of agreement between two raters for nominal scales as discussed by the authors, and they were used to provide a measure of the relative seriousness of the different possible disagreements.
Related Papers (5)
Severity Scoring of Atopic Dermatitis: The SCORAD Index
K.U. Schallreuter,Ch. Levenig,J. Berger,J. Umbert,R.K. Winkelmann,L. Wegener,O. Correia,Olivier Chosidow,P. Saiag,S. Bastuji-Garin,J. Revuz,Jean-Claude Roujeau,R. Situ,D.R. Inman,S.E.G. Fligiel,J. Varani,R.E. Schopf,J. Dobmeyer,T. Dobmeyer,B. Morsches,K. Holubar,G.E. Piérard,O. Bongard,H. Bounameaux,P. Corcuff,J.-L. Lévêque,J. Brasch,E. Christophers,G.T. Nahass,M. Sisto,S.A. Wagner,R.U. Peter,O. Adam,T. Ruzicka,J. McGrath,N.P. Burrows,R. Russell Jones,R.A.J. Eady,S. Veraldi,G. Rizzitelli,G. Lunghi,R. Cardone,R.M. Trüeb,G. Burg,F. Wantke,G. Fleischl,M. Götz,R. Jarisch,G. Tadini,E. Ermacora,S. Cambiaghi,A. Brusasco,R. Cavalli +52 more